BsUFA Research Roadmap Highlights Interchangeability And Reducing Trials
US FDA Invites Feedback On Biosimilar Regulatory Science Pilot Program
Executive Summary
The FDA has published a “Research Roadmap” setting out in detail its areas of interest for the agency’s biosimilar regulatory science pilot program under BsUFA III.
You may also be interested in...
Global Harmonization Efforts Must Go Further
With global regulation of off-patent medicines continuing to evolve, IGBA secretary general Suzette Kox talks about the progress expected from regulatory harmonization for generics and a reduced clinical trial burden for biosimilars.
Global Harmonization Efforts Must Go Further
With global regulation of off-patent medicines continuing to evolve, IGBA secretary general Suzette Kox talks about the progress expected from regulatory harmonization for generics and a reduced clinical trial burden for biosimilars.
Provisionally Interchangeable? FDA Weighs ‘Requirements’ For Pfizer’s Adalimumab
Pfizer has responded to Generics Bulletin’s queries regarding its bid to win an interchangeability designation for its Abrilada (adalimumab-afzb) biosimilar to AbbVie’s Humira reference product.